Emerging Drug Developer: Tolerx

Emerging Drug Developer: Tolerx

Holding promising Phase II data for a monoclonal antibody lined up for a late-stage race to the FDA, Tolerx found itself in the sweet spot of biotech deal making. And GlaxoSmithKline was just one of a number of companies to make a bid for it. For Tolerx CEO Douglas Ringler, the $760 million deal they struck gives the company enough cash to make it all the way through to a BLA. But there's little time for relaxation. Tolerx is engaged in a competitive race to get its CD3 program all the way to the FDA. And it plans to be first. Article

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.